Search This Blog

Tuesday, December 12, 2023

Taxpayers are subsidizing rich electric-vehicle owners — to the tune of billions

 A new report has exposed electric vehicles as wasteful money pits, living up to the adage: If it seems too good to be true, it is.

EV proponents often claim they’re cheaper to own than conventional gas- or diesel-powered vehicles, but that’s simply not true after accounting for the billions of dollars in costs government subsidies and mandates quietly conceal.

The stark reality is the average EV costs at least $53,000 more over 10 years than conventional vehicles, effectively doubling the price of the average new car.

But $22 billion in government handouts to EV owners and manufacturers absorb the extra expense at every stage of the vehicle’s life, from raw-material sourcing to battery charging.

Examining the numbers behind recharging makes this very clear.

While EV advocates claim charging costs are equivalent to $1.21-per-gallon gasoline, the real amount is an order of magnitude more.

Including the charging equipment, subsidies from governments and utilities and other frequently excluded expenses, the true cost of charging an EV is equivalent to $17.33-per-gallon gasoline — but the EV owner pays less than 7% of that.

Over 10 years, almost $12,000 of costs per EV are transferred to utility ratepayers and taxpayers, effectively socializing the price of recharging an EV while keeping the benefits private.

Due to high entry price points — the average EV costs $58,000, the average gas vehicle $33,000 — most EV consumers are affluent.

This is socialism for the rich: a transfer of costs from higher net-worth individuals to middle- and lower-income taxpayers.

It’s the equivalent of levying taxes and fees on public-transportation users and those who walk or bicycle to work and using the money to reduce the price of gasoline.

Everyone without a car would be furious if they found out their money was effectively being given away like this.

But that’s precisely what’s happening with EVs.

One reason EV recharging costs so much is the tremendous energy density of gasoline and diesel.

A single horsepower is 746 watts, so the engine in a typical American sedan is strong enough to provide more than the maximum amount of electricity four typical American homes are wired to handle.

Conversely, recharging a typical EV at home can consume 10,000 watts at any given time, roughly eight times the power an American home consumes on average.

Not only does recharging an EV require a large amount of electricity; it requires infrastructure capable of handling that much power.

Both are very expensive, and America’s electrical grid needs billions of dollars in additional upgrades to support more EVs.

Most major utilities have already conceded they won’t be able to meet the significant capacity additions needed to support proposed EV mandates.

Instead, utilities are reduced to begging customers to recharge during off-peak hours, often offering incentives like lower rates or bill credits.

Both the vast subsidization of EV recharging and the impracticality of making it a widespread practice are emblematic of the production and sale of EVs as well.

Average direct subsidies from federal and state governments amount to almost $9,000 per vehicle over 10 years while direct subsidies from utilities push the amount over $10,000.

But manufacturers receive subsidies too, and regulations force them to produce more and more EVs, even if the vehicles aren’t profitable.

The regulatory environment is so onerous and blatantly favors EVs, auto manufacturers can’t meet a range of federal requirements without shifting an increasing percentage of production toward EVs, even if consumers don’t want them.

Between corporate average fuel economy standards and Environmental Protection Agency rules, “EVs receive nearly seven times more credit,” the Texas Public Policy Foundation report notes, “than they provide in actual fuel economy benefits.”

Thus EVs have become the only way for auto manufacturers to comply with increasingly stringent regulations that will soon make conventional vehicles illegal — no matter how much consumers would rather have a gas- or diesel-powered vehicle.

Subsidies and regulatory credits amount to almost $50,000 per EV over a decade.

Amazingly, even with all these subsidies, mandates and other incentives, the report points out manufacturers are still losing tens of thousands of dollars per EV; consumers clearly don’t want them in the volume they’re being produced. That’s why they’re piling up on dealer lots.

The lack of demand has led GM and Ford to recently announce they must reduce battery production.

What’s even more amazing is the report actually underestimates the total cost of converting America entirely to EVs because it doesn’t attempt to measure many other additional costs.

These include billions of taxpayer dollars spent on electric buses, charging stations at airports, city taxpayer-funded subsidies and California-specific subsidies.

There are also many indirect costs like the disproportionate road damage caused by EVs, which are heavier than conventional vehicles.

Politicians can hide behind words like they hide the true cost of EVs behind subsidies and handouts, but the numbers don’t lie: EVs can cost twice as much as conventional vehicles, and that’s a losing deal for the taxpayers funding these money pits.

E.J. Antoni is a public-finance economist at the Heritage Foundation and a senior fellow at the Committee to Unleash Prosperity. Anthony F. Esposito is a chartered market technician and director of US equity execution at Scotia Capital (USA) Inc.

https://nypost.com/2023/11/07/opinion/taxpayers-are-subsidizing-rich-electric-vehicle-owners-to-the-tune-of-billions/

Cal-Maine Foods temporarily shuts Kansas facility hit by bird flu

 Egg producer Cal-Maine Foods said on Tuesday it had temporarily ceased production at a facility in Kansas after some of the flock tested positive for avian flu.

The company said highly pathogenic avian influenza (HPAI) had affected about 684,000 laying hens, or nearly 1.6% of its total flock.

Cal-Maine said these detections do not present an immediate public health concern and are not a threat to the food supply, according to the U.S. Department of Agriculture (USDA).

It also said that no known HPAI risk associated with eggs were currently in the market and no eggs have been recalled, adding that there were no positive tests for HPAI at any other company locations to date.

Shares of the company were down marginally at $48.80 in extended trading following the news.

More than 72.5 million chickens, turkeys and other birds have been wiped out since the U.S. avian flu outbreak began in February 2022, according to the USDA.

U.S. cases in commercial poultry flocks have increased since October 2023, with experts blaming wild birds for spreading the disease. Kansas had not reported an outbreak in a commercial flock since February 2023, U.S. data shows.

Other large egg-laying operations have also been hit. Ohio confirmed last week that a commercial layer farm with 2.6 million birds was infected and said the birds were being culled.

https://finance.yahoo.com/news/1-cal-maine-foods-temporarily-215134120.html

Icosavax Positive Topline Interim Phase 2 Results for Combo RSV, hMPV Older Adult Vax

 IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data –

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.

https://www.globenewswire.com/news-release/2023/12/12/2794421/0/en/Icosavax-Announces-Positive-Topline-Interim-Phase-2-Results-for-Combination-VLP-Vaccine-Candidate-IVX-A12-Against-RSV-and-hMPV-in-Older-Adults.html

Caribou Biosciences Provides Regulatory Update on B Cell Lymphoma Phase 3

 Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT --

-- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 --

-- Caribou plans to initiate Phase 3 pivotal trial by YE 2024 --

https://www.marketscreener.com/quote/stock/CARIBOU-BIOSCIENCES-INC-125041251/news/Caribou-Biosciences-Provides-Regulatory-Update-on-CB-010-Pivotal-Plan-with-Phase-3-Trial-Initiation-45553818/

Full U.S. Launch of Tandem Source, a New Diabetes Management Platform

 Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers (HCPs). Tandem Source is designed to bring together the features of Tandem’s legacy t:connect, t:connect HCP, and t:connect Portal offerings with new comprehensive data reporting in one central, scalable platform. Tandem Source is now available for all Tandem pump users and their HCPs in the United States, with international availability expected in 2024.

https://www.marketscreener.com/quote/stock/TANDEM-DIABETES-CARE-INC-38066231/news/Tandem-Diabetes-Care-Announces-Full-U-S-Launch-of-Tandem-Source-a-New-Diabetes-Management-Platform-45553943/

Regeneron Pharmaceuticals, Inc.: Morgan Stanley raises the target price from USD 914 to USD 941.

  maintains its overweight rating 

https://www.marketscreener.com/quote/stock/REGENERON-PHARMACEUTICALS-10649/

Walgreens In Talks to Offload £7 Billion UK Pharmacy Chain Boots

 

  • Company considering London listing for Boots pharmacy chain
  • Deal would mark rare blockbuster IPO for beleaguered bourse

Walgreens Boots Alliance Inc. is reviving discussions on a potential exit from its UK drugstore chain Boots, people with knowledge of the matter said, nearly 18 months after a sale process was scrapped.

The company has been holding early talks about ways to separate Boots, which could be valued at about £7 billion ($8.8 billion) in a deal, according to the people. It’s studying a London initial public offering as one possibility, the people said.

https://www.bloomberg.com/news/articles/2023-12-12/walgreens-is-said-to-revive-discussions-on-7-billion-boots-exit